You are here

Article Text

Article menu
Download PDFPDF
Featured correspondence
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
  1. P J Grant
  1. Professor P J Grant, LIGHT Laboratories, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK; p.j.grant{at}leeds.ac.uk

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the editor: It is very disappointing to read a largely uncritical regurgitation of opinion on the clinical use of thiazolidinediones in type 2 diabetes.1

    Far too often, cardiology-based opinions are being published without proper reference to the importance of glycaemic control …

    View Full Text

    Footnotes

    • Competing interests: Declared. The author has received honoraria from GSK, Takeda and Lilly pharmaceuticals for speaker engagements and attendance at advisory board meetings.

    Linked Articles

    • Featured correspondence
      The author's reply
      S Singh C D Furberg
      Heart 2009; 95 332-332 Published Online First: 28 Jan 2009.